Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)

First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC

SAN FRANCISCO – June 4, 2026 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the clinical availability of the ArteraAI Prostate Test (mHSPC), the first digital pathology–based prognostic test designed to help inform treatment planning for patients with metastatic hormone‑sensitive prostate cancer (mHSPC).

mHSPC is a diverse disease state with widely variable outcomes, requiring complex treatment decisions that can significantly impact both survival and quality of life. While traditional clinical factors provide general prognostic insight, they do not offer individualized risk. The ArteraAI Prostate Test (mHSPC) addresses this gap by delivering a patient‑specific estimate of 5‑year prostate cancer–specific mortality (PCSM) in patients treated with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI).

“Artera’s platform was built to bring greater clarity to cancer treatment decisions,” said Andre Esteva, CEO of Artera. “With our expansion into metastatic hormone-sensitive prostate cancer, we are excited to leverage our validated MMAI approach for a more complex stage of disease, helping guide treatment decisions with greater confidence.”

The ArteraAI Prostate Test (mHSPC) builds on Artera’s established biopsy‑based MMAI model used in localized prostate cancer and was validated in the STAMPEDE trial, where the MMAI score was significantly prognostic for prostate cancer–specific mortality (PCSM) in patients receiving ADT plus ARPI.

“As treatment options for metastatic hormone-sensitive prostate cancer have evolved, tools to accurately assess individual patient risk in the context of modern combination therapy have not fully evolved alongside them,” said Calvin Chao, MD, PhD, Vice President of Medical Science at Artera. “This clinically validated test is poised to help clinicians better tailor treatment intensity and duration to the individual patient.”

The ArteraAI Prostate Test (mHSPC) is available through Artera and its commercial partner, Tempus, supporting broad and convenient access within existing clinical workflows.